Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.07
▼(-69.58% Downside)
Action:UpgradedDate:03/03/26
The score is primarily weighed down by weak financial performance—ongoing losses and negative operating/free cash flow—despite low leverage. Technicals further pressure the outlook, with the price below all key moving averages and negative MACD alongside very weak momentum readings. Valuation provides limited support because the negative P/E reflects unprofitable operations and no dividend yield is available.
Positive Factors
Proprietary 3base technology
Ownership of 3base™ provides a durable product differentiation for multiplex PCR assays. This IP-backed platform supports multiple panels and workflows, aiding adoption by labs, enabling product breadth expansion and potential licensing paths that sustain competitive positioning over time.
Negative Factors
Persistent negative cash flow
Sustained negative operating and free cash flow erodes reserves and forces external financing or dilution to fund operations and commercialization. Over months this limits the company's ability to self-fund market expansion and prolongs dependence on capital markets or partners.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary 3base technology
Ownership of 3base™ provides a durable product differentiation for multiplex PCR assays. This IP-backed platform supports multiple panels and workflows, aiding adoption by labs, enabling product breadth expansion and potential licensing paths that sustain competitive positioning over time.
Read all positive factors
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.99M
Dividend YieldN/A
Average Volume (3M)149.45K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth62.81%
EPS Growth16.37%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.03
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$17.10M
Genetic Signatures Ltd. Business Overview & Revenue Model
Company Description
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based...
How the Company Makes Money
GSS makes money primarily by selling molecular diagnostic test kits/assays that clinical laboratories run on PCR instrumentation to generate billable patient test results. Revenue is typically driven by: (1) Consumables/assay sales: recurring sale...
Genetic Signatures Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.08M | 15.90M | 9.77M | 16.94M | 35.42M | 28.28M |
| Gross Profit | -12.87M | 7.78M | 4.31M | -12.74M | 7.21M | 4.27M |
| EBITDA | -15.38M | -16.08M | -19.82M | -13.14M | 4.70M | 3.22M |
| Net Income | -11.27M | -20.10M | -17.86M | -14.05M | 3.06M | 1.76M |
Balance Sheet | ||||||
| Total Assets | 49.04M | 54.63M | 67.29M | 49.08M | 59.65M | 54.05M |
| Cash, Cash Equivalents and Short-Term Investments | 29.87M | 31.30M | 36.25M | 16.35M | 36.90M | 30.12M |
| Total Debt | 653.00K | 791.00K | 1.22M | 0.00 | 34.00K | 399.00K |
| Total Liabilities | 4.95M | 4.54M | 6.18M | 6.16M | 4.85M | 4.71M |
| Stockholders Equity | 44.09M | 50.09M | 61.10M | 42.91M | 54.80M | 49.34M |
Cash Flow | ||||||
| Free Cash Flow | -10.67M | -13.19M | -14.91M | -20.55M | 6.82M | -784.00K |
| Operating Cash Flow | -9.60M | -12.29M | -10.12M | -12.45M | 9.81M | 4.20M |
| Investing Cash Flow | -13.57M | -24.30M | -4.79M | -8.09M | -2.99M | -4.98M |
| Financing Cash Flow | -455.00K | 7.79M | 34.81M | -23.00K | -101.00K | -190.00K |
Genetic Signatures Ltd. Technical Analysis
Negative
0.24
Price Trends
0.12
Negative
0.20
Negative
0.26
Negative
Market Momentum
-0.01
Negative
42.51
Neutral
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.12, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.51 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GSS.
Genetic Signatures Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$56.13M | 10.72 | 72.82% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$63.51M | -4.75 | -476.27% | ― | ― | 56.42% | |
49 Neutral | AU$203.42M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
42 Neutral | AU$37.79M | -2.45 | -164.22% | ― | ― | 23.85% | |
41 Neutral | AU$19.99M | -2.23 | -23.93% | ― | 62.81% | 16.37% | |
38 Underperform | AU$48.57M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
* Healthcare Sector Average
AU:GSS
Genetic Signatures Ltd.
0.09
-0.41
-82.40%
AU:BDX
BCAL Diagnostics Limited
0.10
<0.01
2.00%
AU:RHY
Rhythm Biosciences Ltd.
0.19
0.11
131.25%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.26
0.24
1175.00%
AU:CTE
Cryosite Limited
1.15
0.35
43.75%
AU:IIQ
Inoviq Ltd
0.35
-0.06
-13.75%
Genetic Signatures Ltd. Corporate Events
Genetic Signatures Sets Growth Path in Molecular Diagnostics for 1H FY26
Feb 25, 2026
Genetic Signatures Ltd., an ASX-listed molecular diagnostics firm headquartered in Sydney, focuses on PCR-based infectious disease testing using its proprietary 3base technology. The company serves pathology providers and hospitals with gastroente...
Genetic Signatures Options Lapse, Simplifying Capital Structure
Feb 10, 2026
Genetic Signatures Limited has notified the market of the cessation of certain securities following the lapse of conditional rights attached to two option classes. A total of 247,500 options under the GSSAB code and 40,000 options under the GSSAC ...
Genetic Signatures Strengthens Leadership with Interim Managing Director Appointment
Feb 5, 2026
Genetic Signatures Limited has appointed non-executive director Anne Lockwood as interim Managing Director for six months, bolstering its leadership with more than 30 years’ experience in finance, risk management, MA and capital markets, and...
Genetic Signatures Names Maria Halasz as CEO to Drive Next Growth Phase
Feb 1, 2026
Genetic Signatures Limited has appointed experienced life sciences executive Maria Halasz as Chief Executive Officer, effective 2 March 2026, as the company positions itself for its next phase of international growth. Halasz, who has more than two...
Genetic Signatures Posts Solid Cash Position as International GI Diagnostics Rollout Gains Traction
Jan 19, 2026
Genetic Signatures reported unaudited second-quarter FY26 sales of $3.3 million, reflecting a seasonal downturn in respiratory testing in Australia, with revenue contributions now coming from Australia, EMEA and the US and a rising share from inte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.